PubMed · 1985 · 28 citations · 0 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyRheumatologyTherapeutic Drug MonitoringChronic InflammationDose OptimizationInflammatory ArthritisJoint DiseaseRheumatoid ArthritisInjection FrequencyMethotrexate NephrotoxicityMethotrexate Toxicity PreventionRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis TherapyRheumatologic Toxicity ManagementSerum Drug Level InterpretationSerum Level Monitoring
Methotrexate (MTX) is being used with increasing frequency in the treatment of inflammatory arthritis. Seventy-one patients have been treated with MTX with only five ceasing treatment because of toxicity. From a study of the serum levels of this drug, we believe that 10 mg intramuscularly once per week should be an optimum method of treating arthritis. The measurement of a 24 hour serum level of MTX, which normally is less than 0.01 mumole/litre after 10 mg I.M., should aid in identifying those patients more at risk of developing toxicity.